兆科眼科收购硫酸阿托品滴眼液全球权利,国内仅一家药企获批

红星资本局
Jul 15

红星资本局7月15日消息,7月13日,兆科眼科(6622.HK)发布公告称,已收购NVK002(硫酸阿托品滴眼液)的全球权利。公告显示,NVK002旨在减慢儿童近视加深,能有效解决低浓度阿托品的不稳定性问题。  ▲兆科眼科公告截图  红星资本局注意到,早在2020年10月,兆科眼科便从Nevakar获得了NVK002在大中华区、韩国及若干东南亚国家的独家许可。根据本次协议条款,兆科眼科将取得与...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10